Ketogenesis

Overview

Ketogenesis is the metabolic pathway by which the liver produces ketone bodies — acetoacetate, beta-hydroxybutyrate, and acetone — from acetyl-CoA derived primarily from beta-oxidation of fatty acids. This pathway becomes active when carbohydrate availability is low and fatty acid oxidation is high: during prolonged fasting, starvation, very-low-carbohydrate diets, and uncontrolled diabetes.

Ketone bodies serve as a critical alternative fuel source, particularly for the brain, which cannot oxidize fatty acids directly due to the blood-brain barrier's impermeability to long-chain fatty acids. During prolonged fasting, ketone bodies can supply up to 60-70% of the brain's energy needs, reducing the demand for gluconeogenesis and thereby sparing muscle protein from catabolism.

How It Works

Pathway Steps

Ketogenesis occurs exclusively in the mitochondrial matrix of hepatocytes:

1. Condensation — Two molecules of acetyl-CoA condense to form acetoacetyl-CoA (catalyzed by thiolase, running in reverse of beta-oxidation)
2. HMG-CoA formation — HMG-CoA synthase adds a third acetyl-CoA to form 3-hydroxy-3-methylglutaryl-CoA (HMG-CoA) — the rate-limiting step
3. Cleavage — HMG-CoA lyase cleaves HMG-CoA to produce acetoacetate and acetyl-CoA
4. Reduction — Beta-hydroxybutyrate dehydrogenase reduces acetoacetate to beta-hydroxybutyrate (the predominant circulating ketone body) using NADH
5. Spontaneous decarboxylation — A small fraction of acetoacetate spontaneously decarboxylates to acetone (exhaled or excreted)

Why the Liver Cannot Use Its Own Ketones

Hepatocytes lack succinyl-CoA:acetoacetate CoA-transferase (thiophorase), the enzyme required to activate ketone bodies for oxidation. This ensures the liver exports ketone bodies to extrahepatic tissues (brain, heart, skeletal muscle, kidneys) rather than consuming them.

Regulation

The rate of ketogenesis depends on three factors: (1) the rate of lipolysis in adipose tissue, determining fatty acid supply; (2) the activity of CPT1, controlling fatty acid entry into mitochondria for beta-oxidation; and (3) the activity of HMG-CoA synthase, the committed step. Low insulin and elevated glucagon shift all three factors toward increased ketogenesis.

Key Components

• HMG-CoA synthase — Rate-limiting enzyme of ketogenesis
• Acetyl-CoA — The substrate, derived from beta-oxidation
• Beta-hydroxybutyrate — The major circulating ketone body (approximately 78% of total)
• Acetoacetate — The first ketone produced, interconvertible with beta-hydroxybutyrate
• Malonyl-CoA — When low (fasting state), CPT1 activity increases, feeding more acetyl-CoA into the ketogenic pathway

Peptide Connections

Ketogenesis is regulated by the hormonal balance between catabolic and anabolic peptide signals:

Glucagon is the primary hormonal driver of ketogenesis. During fasting, elevated glucagon activates hormone-sensitive lipase in adipose tissue (indirectly, by lowering insulin), increases hepatic fatty acid uptake, reduces malonyl-CoA levels (relieving CPT1 inhibition), and promotes beta-oxidation. The resulting excess acetyl-CoA, beyond what the Krebs cycle can accommodate (due to oxaloacetate diversion to gluconeogenesis), is channeled into ketogenesis.

Insulin is the primary suppressor of ketogenesis. Even small amounts of insulin powerfully inhibit lipolysis, reduce fatty acid delivery to the liver, and maintain malonyl-CoA levels that restrain CPT1. In type 1 diabetes, absolute insulin deficiency causes unrestrained ketogenesis, leading to diabetic ketoacidosis (DKA).

Semaglutide and GLP-1 receptor agonists influence ketogenesis indirectly by modulating insulin and glucagon secretion. During weight loss with these agents, a degree of ketogenesis may occur as fat mobilization increases, but the preserved insulin secretory capacity prevents pathological ketone accumulation.

Growth hormone, stimulated by peptides such as ipamorelin and sermorelin acting through the growth hormone axis, promotes lipolysis and fatty acid availability. During fasting, GH contributes to the substrate supply for ketogenesis while simultaneously supporting protein preservation.

Clinical Significance

Diabetic ketoacidosis (DKA) represents the pathological extreme of ketogenesis, occurring when absolute or relative insulin deficiency permits uncontrolled lipolysis and ketone production. Blood ketone levels can exceed 20 mmol/L (normal fasting: 0.1-0.3 mmol/L; nutritional ketosis: 0.5-3.0 mmol/L), causing metabolic acidosis, dehydration, and potentially death.

Nutritional or therapeutic ketosis, achieved through fasting or ketogenic diets, is being investigated for neurological conditions including epilepsy (where ketogenic diets are established therapy), Alzheimer's disease, and brain tumors. The neuroprotective effects of ketone bodies may relate to improved mitochondrial function, reduced oxidative stress, and anti-inflammatory signaling.

Related Topics

• Beta-Oxidation — Provides the acetyl-CoA substrate for ketogenesis
• Gluconeogenesis — Competes for oxaloacetate, promoting ketogenesis when active
• Lipogenesis — The opposing fed-state pathway
• Insulin Signaling Cascade — Hormonal suppression of ketogenesis
• Growth Hormone Release — Promotes lipolysis supporting ketogenic substrate supply